Table 3.
Summary odds ratios of hepatocellular carcinoma for hepatitis B virus mutations after matching or stratification*
| PreS |
C1653T |
T1753V |
A1762T/G1764A |
|||||
| Matching or stratification | No. of case subjects/No. of control subjects | OR (95% CI) | No. of case subjects/No. of control subjects | OR (95% CI) | No. of case subjects/No. of control subjects | OR (95% CI) | No. of case subjects/No. of control subjects | OR (95% CI) |
| Matching | ||||||||
| No | 267/846 | 3.80 (2.25 to 6.41) | 170/445 | 3.14 (1.98 to 4.99) | 155/395 | 2.68 (1.10 to 6.54) | 945/1614 | 4.59 (2.70 to 7.80) |
| Age | 121/288 | 3.92 (2.12 to 7.25) | 525/798 | 2.56 (1.98 to 3.32) | 657/1002 | 2.17 (1.46 to 3.22) | 1145/1685 | 3.16 (2.14 to 4.65) |
| Age + sex | 74/238 | 5.18 (2.52 to 10.63) | 467/569 | 2.42 (1.81 to 3.22) | 467/569 | 1.96 (1.17 to 3.27) | 855/1103 | 2.74 (1.68 to 4.49) |
| Age + sex + HBeAg status | 24/136 | 3.58 (1.44 to 8.89) | 401/439 | 2.64 (1.92 to 3.62) | 401/439 | 1.74 (0.93 to 3.24) | 482/655 | 3.81 (2.68 to 5.43) |
| Age + sex + HBeAg status + HBV genotype | — | — | 120/160 | 3.77 (2.26 to 6.27) | 120/160 | 2.03 (0.75 to 5.47) | 120/160 | 3.37 (1.64 to 6.92) |
| HBV genotype | ||||||||
| B | 91/261 | 3.81 (1.85 to 7.88) | — | — | — | — | 217/239 | 13.00 (3.72 to 45.30) |
| C | 142/456 | 6.55 (2.62 to 16.35) | 430/863 | 2.81 (2.16 to 3.64) | 421/805 | 2.19 (1.37 to 3.52) | 609/1000 | 4.44 (2.62 to 7.53) |
| C1 | — | — | 77/119 | 1.56 (0.74 to 3.29) | 77/119 | 3.10 (1.67 to 5.74) | 77/119 | 3.18 (1.44 to 7.05) |
| C2 | — | — | 191/288 | 2.47 (1.65 to 3.71) | 191/288 | 2.46 (1.61 to 3.75) | 191/288 | 2.83 (1.62 to 4.92) |
| Study location | ||||||||
| China + Taiwan + Hong Kong | 187/407 | 5.33 (2.34 to 12.13) | 246/393 | 2.45 (1.52 to 3.94) | 378/597 | 2.77 (1.16 to 6.59) | 1198/3122 | 4.00 (2.60 to 6.17) |
| Japan | 24/136 | 3.58 (1.44 to 8.89) | 169/378 | 3.19 (2.11 to 4.83) | 138/309 | 3.33 (2.10 to 5.27) | 214/396 | 3.27 (1.45 to 7.35) |
| Korea | 112/308 | 2.62 (1.66 to 4.16) | 60/124 | 2.93 (1.47 to 5.82) | 60/124 | 2.41 (1.21 to 4.80) | 66/144 | 4.65 (2.14 to 10.12) |
| Asia | 323/851 | 3.87 (2.45 to 6.09) | 595/1039 | 2.48 (1.93 to 3.19) | 756/1298 | 2.58 (1.73 to 3.84) | 1834/4022 | 3.87 (2.75 to 5.45) |
| Areas excluding Asia | — | — | — | — | — | — | 361/603 | 3.62 (1.57 to 8.37) |
| HBeAg status | ||||||||
| Positive | — | — | 109/148 | 4.49 (2.21 to 9.14) | 109/112 | 3.34 (1.82 to 6.14) | 134/163 | 6.58 (3.35 to 12.93) |
| Negative | — | — | 176/302 | 2.77 (1.87 to 4.11) | 176/302 | 2.90 (1.93 to 4.34) | 201/334 | 4.76 (2.80 to 8.10) |
| Quality score | ||||||||
| ≥8 | 63/69 | 7.64 (3.52 to 16.58) | 459/510 | 2.43 (1.82 to 3.25) | 607/733 | 1.84 (1.24 to 2.72) | 999/2878 | 2.93 (2.01 to 4.28) |
| 5–7 | 261/863 | 3.41 (2.13 to 5.44) | 236/733 | 3.17 (2.21 to 4.54) | 205/664 | 3.52 (1.89 to 6.54) | 584/1112 | 4.27 (2.58 to 7.08) |
| ≤4 | 64/202 | 2.99 (1.51 to 5.90) | — | — | — | — | 634/734 | 3.53 (1.69 to 7.34) |
*
CI = confidence interval; HBeAg = hepatitis B e antigen; — = data not available; HBV = hepatitis B virus; OR = odds ratio.